2018 Peripheral Arterial Disease (PAD) Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Peripheral Arterial Disease (PAD) Market
Peripheral Arterial Disease is a condition in which plaque or fatty deposits build up in the arteries which supply blood to the leg muscles. It can cause serious implications such as myocardial infarction, vascular dementia, stroke etc. An estimated 0.2 billion population is affected worldwide and the market size of Peripheral Arterial Disease (PAD) is estimated to be around $4.5 billion.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Peripheral Arterial Disease (PAD) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Peripheral Arterial Disease (PAD) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Peripheral Arterial Disease (PAD) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Peripheral Arterial Disease (PAD) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Peripheral Arterial Disease (PAD) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Peripheral Arterial Disease (PAD) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 PERIPHERAL ARTERIAL DISEASE (PAD) PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Peripheral Arterial Disease (PAD) Pipeline Snapshot
2.3 Peripheral Arterial Disease (PAD) Pipeline by Phase
2.4 Peripheral Arterial Disease (PAD) Pipeline by Company
2.5 Peripheral Arterial Disease (PAD) Pipeline by Mechanism of Action
3 PERIPHERAL ARTERIAL DISEASE (PAD)- COMPANY WISE PIPELINE ANALYSIS
480 Biomedical, Inc.
Alucent Medical Inc
Anaeropharma Science, Inc.
AnGes MG Inc
AngioSoma Inc
apceth Biopharma GmbH
Athera Biotechnologies AB
Athersys Inc
Bayer AG
Betagenon AB
BiogenCell Ltd
CardioVascular BioTherapeutics Inc
Celularity Inc
Exodos Life Sciences LP
Foresee Pharmaceuticals Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
Juventas Therapeutics Inc
LipimetiX Development Inc
MultiGene Vascular Systems (MGVS) Ltd
Nangiotx Inc
Novartis AG
Nuo Therapeutics Inc
Pluristem Therapeutics Inc.
G. Pohl-Boskamp GmbH & Co. KG
Proteon Therapeutics Inc
Resverlogix Corporation
Reven Pharmaceuticals Inc
RHEACELL GmbH & Co. KG
SK Chemicals Co.,Ltd
Stemedica Cell Technologies Inc
Symic Biomedical Inc
VESSL Therapeutics Ltd
ViroMed Co Ltd
Yuyu Pharma Inc
4 PERIPHERAL ARTERIAL DISEASE (PAD) R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PERIPHERAL ARTERIAL DISEASE (PAD) PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 PERIPHERAL ARTERIAL DISEASE (PAD) PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Peripheral Arterial Disease (PAD) Pipeline Snapshot
2.3 Peripheral Arterial Disease (PAD) Pipeline by Phase
2.4 Peripheral Arterial Disease (PAD) Pipeline by Company
2.5 Peripheral Arterial Disease (PAD) Pipeline by Mechanism of Action
3 PERIPHERAL ARTERIAL DISEASE (PAD)- COMPANY WISE PIPELINE ANALYSIS
480 Biomedical, Inc.
Alucent Medical Inc
Anaeropharma Science, Inc.
AnGes MG Inc
AngioSoma Inc
apceth Biopharma GmbH
Athera Biotechnologies AB
Athersys Inc
Bayer AG
Betagenon AB
BiogenCell Ltd
CardioVascular BioTherapeutics Inc
Celularity Inc
Exodos Life Sciences LP
Foresee Pharmaceuticals Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
Juventas Therapeutics Inc
LipimetiX Development Inc
MultiGene Vascular Systems (MGVS) Ltd
Nangiotx Inc
Novartis AG
Nuo Therapeutics Inc
Pluristem Therapeutics Inc.
G. Pohl-Boskamp GmbH & Co. KG
Proteon Therapeutics Inc
Resverlogix Corporation
Reven Pharmaceuticals Inc
RHEACELL GmbH & Co. KG
SK Chemicals Co.,Ltd
Stemedica Cell Technologies Inc
Symic Biomedical Inc
VESSL Therapeutics Ltd
ViroMed Co Ltd
Yuyu Pharma Inc
4 PERIPHERAL ARTERIAL DISEASE (PAD) R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PERIPHERAL ARTERIAL DISEASE (PAD) PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Peripheral Arterial Disease (PAD) Pipeline by Phase, H2- 2018
Figure 2: Peripheral Arterial Disease (PAD) Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Peripheral Arterial Disease (PAD) Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Peripheral Arterial Disease (PAD) Pipeline by Phase, H2- 2018
Figure 2: Peripheral Arterial Disease (PAD) Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Peripheral Arterial Disease (PAD) Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Peripheral Arterial Disease (PAD) Pipeline by Phase, H2- 2018
Peripheral Arterial Disease (PAD) Pipeline by Companies, H2- 2018
Peripheral Arterial Disease (PAD) Pipeline by Mechanism of Action, H2- 2018
Table 1: 480 Biomedical, Inc. Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 2: Alucent Medical Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 3: Anaeropharma Science, Inc. Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 4: AnGes MG Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 5: AngioSoma Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 6: apceth Biopharma GmbH Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 7: Athera Biotechnologies AB Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 8: Athersys Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 9: Bayer AG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 10: Betagenon AB Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 11: BiogenCell Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 12: CardioVascular BioTherapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 13: Celularity Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 14: Exodos Life Sciences LP Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 15: Foresee Pharmaceuticals Co Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 16: Hemostemix Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 17: ID Pharma Co Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 18: Juventas Therapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 19: LipimetiX Development Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 20: MultiGene Vascular Systems (MGVS) Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 21: Nangiotx Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 22: Novartis AG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 23: Nuo Therapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 24: Pluristem Therapeutics Inc. Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 25: G. Pohl-Boskamp GmbH & Co. KG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 26: Proteon Therapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 27: Resverlogix Corporation Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 28: Reven Pharmaceuticals Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 29: RHEACELL GmbH & Co. KG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 30: SK Chemicals Co.,Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 31: Stemedica Cell Technologies Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 32: Symic Biomedical Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 33: VESSL Therapeutics Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 34: ViroMed Co Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 35: Yuyu Pharma Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Peripheral Arterial Disease (PAD) Pipeline by Phase, H2- 2018
Peripheral Arterial Disease (PAD) Pipeline by Companies, H2- 2018
Peripheral Arterial Disease (PAD) Pipeline by Mechanism of Action, H2- 2018
Table 1: 480 Biomedical, Inc. Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 2: Alucent Medical Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 3: Anaeropharma Science, Inc. Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 4: AnGes MG Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 5: AngioSoma Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 6: apceth Biopharma GmbH Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 7: Athera Biotechnologies AB Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 8: Athersys Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 9: Bayer AG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 10: Betagenon AB Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 11: BiogenCell Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 12: CardioVascular BioTherapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 13: Celularity Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 14: Exodos Life Sciences LP Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 15: Foresee Pharmaceuticals Co Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 16: Hemostemix Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 17: ID Pharma Co Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 18: Juventas Therapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 19: LipimetiX Development Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 20: MultiGene Vascular Systems (MGVS) Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 21: Nangiotx Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 22: Novartis AG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 23: Nuo Therapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 24: Pluristem Therapeutics Inc. Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 25: G. Pohl-Boskamp GmbH & Co. KG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 26: Proteon Therapeutics Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 27: Resverlogix Corporation Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 28: Reven Pharmaceuticals Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 29: RHEACELL GmbH & Co. KG Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 30: SK Chemicals Co.,Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 31: Stemedica Cell Technologies Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 32: Symic Biomedical Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 33: VESSL Therapeutics Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 34: ViroMed Co Ltd Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
Table 35: Yuyu Pharma Inc Peripheral Arterial Disease (PAD) Pipeline Drugs, H2- 2018
